REGULATORY

Online NDA Submission Starts in Japan: MHLW/PMDA

July 4, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese regulators on July 1 started accepting the online submission of new drug applications (NDAs) as well as other documents related to pharmaceuticals and medical devices. The submission system will be available 24/7, except during maintenance. The Ministry of Health,…

To read the full story

Online Submissions for Generic Approval to Start from January
November 14, 2022
Online Submissions for Partial Changes of Generics to Start from October
July 29, 2022
Japanese Regulators to Accept Online NDA Submissions from July
May 23, 2022

REGULATORY

LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…